See more : Fancamp Exploration Ltd. (FNCJF) Income Statement Analysis – Financial Results
Complete financial analysis of Scinai Immunotherapeutics Ltd. (SCNI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scinai Immunotherapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Daiichi Sankyo Company, Limited (DSKYF) Income Statement Analysis – Financial Results
- Brass Corporation (2424.T) Income Statement Analysis – Financial Results
- Harte Hanks, Inc. (HHS) Income Statement Analysis – Financial Results
- General Electric Company (GEC.DE) Income Statement Analysis – Financial Results
- Flying Nickel Mining Corp. (FLYNF) Income Statement Analysis – Financial Results
Scinai Immunotherapeutics Ltd. (SCNI)
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 167.98K | 76.22K | 66.96K | 73.42K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -167.98K | -76.22K | -66.96K | -73.42K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.21M | 5.77M | 3.25M | 16.01M | 19.88M | 19.27M | 5.58M | 2.44M | 2.76M | 1.65M | 1.94M | 1.61M | 1.53M | 1.80M | 805.34K | 882.39K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.51M | 5.30M | 7.63M | 5.19M | 2.81M | 1.38M | 1.40M | 1.07M | 871.81K | 680.13K | 631.56K | 574.69K | 602.75K | 668.83K | 299.68K | 343.07K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -23.49M | 1.00 | -38.24K | -185.65K | -416.06K | -726.29K | -243.56K | -366.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.72M | 11.06M | 10.87M | -2.28M | 22.69M | 20.61M | 6.80M | 3.09M | 2.90M | 2.09M | 2.20M | 2.19M | 2.13M | 2.47M | 1.11M | 1.23M |
| Cost & Expenses | 9.72M | 11.06M | 10.87M | -2.28M | 22.69M | 20.61M | 6.80M | 3.09M | 2.90M | 2.09M | 2.20M | 2.38M | 2.30M | 2.54M | 1.17M | 1.30M |
| Interest Income | 122.68K | 8.10M | 928.76 | -9.71K | 8.30K | 1.35M | 5.04K | 14.38K | 2.83K | 21.19K | 37.80K | 65.04K | 129.34K | 85.62K | 8.66K | 89.89K |
| Interest Expense | -317.00 | 5.05M | -3.15M | 338.76K | 4.28M | 3.78M | -129.95 | 100.00 | 7.80 | 1.69K | -1.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 514.00K | 562.00K | 471.00K | 468.56K | 461.69K | 69.53K | 123.55K | 162.32K | 161.62K | 173.75K | 204.46K | 190.18K | 167.98K | 76.22K | 66.96K | 73.42K |
| EBITDA | -9.19M | -10.50M | -10.39M | 2.75M | -22.21M | -20.54M | -6.67M | -2.93M | -2.74M | -1.92M | -2.00M | -2.24M | -1.99M | -2.41M | -1.10M | -1.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.72M | -11.06M | -10.87M | 2.28M | -22.69M | -20.61M | -6.80M | -3.09M | -2.90M | -2.09M | -2.20M | -2.38M | -2.30M | -2.54M | -1.17M | -1.30M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.22M | 5.27M | 2.67M | -3.67M | -8.93M | -2.85M | -3.13M | 704.94K | 283.33K | 97.02K | -113.91K | -51.25K | 142.22K | 53.68K | 6.87K | 88.21K |
| Income Before Tax | -6.50M | -5.80M | -8.21M | -1.39M | -31.62M | -23.46M | -9.93M | -2.38M | -2.62M | -1.99M | -2.32M | -2.43M | -2.16M | -2.49M | -1.17M | -1.21M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -6.50M | -5.80M | -8.21M | -1.39M | -31.62M | -23.46M | -9.93M | -2.38M | -2.62M | -1.99M | -2.32M | -2.43M | -2.16M | -2.49M | -1.17M | -1.21M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.64 | -30.74 | -58.14 | -12.51 | -387.21 | -358.95 | -197.58 | -70.58 | -99.22 | -146.80 | -193.35 | -230.45 | -223.97 | -279.13 | -173.14 | -189.82 |
| EPS Diluted | -16.64 | -30.74 | -58.14 | -12.51 | -387.21 | -358.95 | -197.58 | -70.58 | -99.22 | -146.80 | -193.33 | -230.45 | -223.97 | -279.13 | 0.00 | -189.82 |
| Weighted Avg Shares Out | 390.66K | 188.52K | 141.14K | 110.81K | 81.66K | 65.35K | 50.26K | 33.77K | 26.38K | 13.57K | 11.99K | 10.53K | 9.65K | 8.91K | 6.73K | 6.38K |
| Weighted Avg Shares Out (Dil) | 390.66K | 188.52K | 141.14K | 110.82K | 81.66K | 65.36K | 50.26K | 33.77K | 26.38K | 13.57K | 11.99K | 10.53K | 9.65K | 8.91K | 0.00 | 6.38K |
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.
JERUSALEM , June 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it...
Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement
JERUSALEM , June 7, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that...
Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance
JERUSALEM , May 24, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (the "Company") (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced the receipt...
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update
JERUSALEM , May 15, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today...
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal
The Board has Approved a Ratio Change of the ADSs to Non-traded Ordinary Shares (equivalent to a reverse split) Designed to Regain Compliance JERUSALEM , May 6, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on...
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
JERUSALEM , April 10, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that the company's...
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
JERUSALEM , April 8, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that Ayana Pharma Ltd.
Scinai leadership to attend BIO-Europe Spring 2024
Showcasing Company's cGMP biologics CDMO and innovative NanoAb pipeline JERUSALEM , March 12, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its...
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
JERUSALEM , Feb. 29, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced that it will be...
Scinai Welcomes Liat Halpert as Head of Business Development and Sales
JERUSALEM , Feb. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat...
Source: https://incomestatements.info
Category: Stock Reports